Home/ Stocks/ BCDA

BioCardia, Inc. Common Stock

BCDA XNAS

$1.21 +0.05 (+3.81%) ▲ 15-min delayed

Open

$1.19

High

$1.23

Low

$1.12

Volume

42.3K

Market Cap

$12.74M

About BioCardia, Inc. Common Stock

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 17 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-1,483,000	$-0.24
Q2 2025	$0	$-2,049,000	$-0.40
Q1 2025	$0	$-2,712,000	$-0.59
FY 2024	$58.0K	$-7,946,000	$-2.90

Earnings & Analyst Ratings

Next Earnings: Tue, May 12, 2026

Calendar →

Related Market News

No specific coverage for BCDA yet. Check out our latest market news or earnings calendar.

Get BCDA Alerts

Stay ahead with breaking news, price alerts, and expert analysis on BioCardia, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.